Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia.
作者： A. R. Bentivoglio , E. Di Stasio , D. Mulas , M. L. Cerbarano , T. Ialongo
DOI: 10.1007/S12640-017-9737-6
关键词:
摘要: Botulinum toxin is considered as first-line therapy for cervical dystonia, but few papers have addressed these issues in the long term. Aim of this study was to investigate long-term efficacy and safety abobotulinumtoxin A (A/Abo) patients with primary dystonia. Consecutive who received at least six injections A/Abo were included. Safety assessed on patients’ self-reports. Efficacy by recording total duration benefit, maximum efficacy, disease severity measured means Tsui score, pain intensity evaluated visual analog scale (VAS). Thirty-nine PCD The mean dose injected 701.5 ± 280.6 U. clinical improvement 93.0 30.7 days, while 77.1 27.1 days. VAS before 4 weeks after injection 4.4 1.8 1.6, respectively. score treatment 5.7 3.5 1.5, Doses significantly increased over time, displayed a tendency decrease along time. Side effects occurred 19.6% all treatments severe only four injections. results our confirm effectiveness profile
springer.com
core.ac.uk 
sci-hub.se 参考文章(54)
R. L. Rosales, D. Dressler, On muscle spindles, dystonia and botulinum toxin. European Journal of Neurology. ,vol. 17, pp. 71- 80 ,(2010) , 10.1111/J.1468-1331.2010.03056.X
C. Colosimo, A. Suppa, G. Fabbrini, M. Bologna, A. Berardelli, Craniocervical dystonia: clinical and pathophysiological features European Journal of Neurology. ,vol. 17, pp. 15- 21 ,(2010) , 10.1111/J.1468-1331.2010.03045.X
G-Y.R. Hsiung, S.K. Das, R. Ranawaya, A.-L. Lafontaine, O. Suchowersky, Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Movement Disorders. ,vol. 17, pp. 1288- 1293 ,(2002) , 10.1002/MDS.10252
F. Gilio, A. Curr�, C. Lorenzano, N. Modugno, M. Manfredi, A. Berardelli, Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Annals of Neurology. ,vol. 48, pp. 20- 26 ,(2000) , 10.1002/1531-8249(200007)48:1<20::AID-ANA5>3.0.CO;2-U
Daniel Truong, Matthew Brodsky, Mark Lew, Allison Brashear, Joseph Jankovic, Eric Molho, Olga Orlova, Sofia Timerbaeva, Global Dysport Cervical Dystonia Study Group, Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia Parkinsonism & Related Disorders. ,vol. 16, pp. 316- 323 ,(2010) , 10.1016/J.PARKRELDIS.2010.03.002
B. Mohammadi, N. Buhr, H. Bigalke, K. Krampfl, R. Dengler, K. Kollewe, A long-term follow-up of botulinum toxin A in cervical dystonia. Neurological Research. ,vol. 31, pp. 463- 466 ,(2009) , 10.1179/174313209X405137
Nicte I. Mejia, Kevin Dat Vuong, Joseph Jankovic, Long‐term botulinum toxin efficacy, safety, and immunogenicity Movement Disorders. ,vol. 20, pp. 592- 597 ,(2005) , 10.1002/MDS.20376
Guido Maria Filippi, Pierangelo Errico, Rosamaria Santarelli, Bruno Bagolini, Ermanno Manni, Botulinum a Toxin Effects on Rat Jaw Muscle Spindles Acta Oto-laryngologica. ,vol. 113, pp. 400- 404 ,(1993) , 10.3109/00016489309135834
Daniel Truong, Drake D. Duane, Joseph Jankovic, Carlos Singer, Lauren C. Seeberger, Cynthia L. Comella, Mark F. Lew, Robert L. Rodnitzky, Fabio O. Danisi, James P. Sutton, P. David Charles, Robert A. Hauser, Geoffrey L. Sheean, Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Movement Disorders. ,vol. 20, pp. 783- 791 ,(2005) , 10.1002/MDS.20403
J. Wissel, P. Kanovsky, E. Ruzicka, M. Bares, H. Hortova, H. Streitova, R. Jech, J. Roth, C. Brenneis, J. Müller, P. Schnider, E. Auff, A. Richardson, W. Poewe, Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. Journal of Neurology. ,vol. 248, pp. 1073- 1078 ,(2001) , 10.1007/S004150170028